Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

PEA cycle length: what human studies ran

Not approved — research use onlyAHuman trial evidence
Short answer: there is no established PEA cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. The knee osteoarthritis and diabetic neuropathic pain trials each treated for 8 weeks 19,20; the spinal cord injury trial treated for 12 weeks with a 1-week baseline diary period 21.
  2. The major depressive disorder trial ran 6 weeks, the autism trial 10 weeks with an interim assessment at week 5, and the acute mania trial 6 weeks 22,23,24.
  3. The COVID-19 inflammation trial supplemented for 4 weeks with blood sampling at baseline and week 4 25; the healthy-volunteer pain-model crossover used 4-week periods 7.
  4. The menstrual pain crossover used single administrations at pain onset with observation for up to 4 hours; the PTSD trial followed participants for 18 months 9,10.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • PEA combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established PEA cycle length?
No. Human studies administered PEA for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of PEA?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
PEA dosing reference Full research page

References

  1. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations Br J Pharmacol. 2017
  2. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials Nutrients. 2023
  3. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide Mol Pharmacol. 2005
  4. Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations Brain Behav Immun Health. 2025
  5. Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding Nutr Rev. 2025
  6. Efficacy, safety, and tolerability of palmitoylethanolamide in the management of diabetic neuropathic pain: a systematic review and meta-analysis J Diabetes Metab Disord. 2026
  7. The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers - A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial Nutrients. 2022
  8. Palmitoylethanolamide Does Not Affect Recovery from Exercise-Induced Muscle Damage in Healthy Males Med Sci Sports Exerc. 2024
  9. Palmitoylethanolamide (Levagen+) for acute menstrual pain: a randomized, crossover, double-blind, placebo-controlled trial Women Health. 2025
  10. Targeting PTSD with ultramicronized palmitoylethanolamide: Results from a randomized trial integrating pharmacotherapy and cognitive behavioral therapy J Psychiatr Res. 2026
  11. Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity J Neuroinflammation. 2019
  12. Pharmacokinetics of micronized and water dispersible palmitoylethanolamide in comparison with standard palmitoylethanolamide following single oral administration in male Sprague-Dawley rats Indian J Pharmacol. 2025
  13. PubChem compound record for palmitoylethanolamide (CID 4671; N-(2-hydroxyethyl)hexadecanamide, CAS 544-31-0) PubChem. 2026
  14. Drugs@FDA application data queried through openFDA for palmitoylethanolamide and palmidrol (no matching application record returned on 22 October 2026) openFDA / Drugs@FDA. 2026
  15. Dietary Supplement Label Database (DSLD) search for palmitoylethanolamide, returning 718 US dietary supplement labels on 22 October 2026 NIH Office of Dietary Supplements. 2026
  16. International Standard: Prohibited List 2026 (full-document search for palmitoylethanolamide and ethanolamide returned no named entry) World Anti-Doping Agency. 2026
  17. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIA Study of FSD201 (Ultramicronized PEA) + Standard of Care Vs SOC in the Treatment of Hospitalized Patients With COVID-19 (NCT04619706; terminated) ClinicalTrials.gov. 2022
  18. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (updated May 14, 2026; palmitoylethanolamide not listed in categories 1, 2 or 3) FDA. 2026
  19. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis Inflammopharmacology. 2019
  20. A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain Inflammopharmacology. 2022
  21. Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial Pain. 2016
  22. Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial J Affect Disord. 2018
  23. Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial J Psychiatr Res. 2018
  24. Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: A randomized, double-blind, placebo-controlled trial Psychiatry Clin Neurosci. 2022
  25. Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled Trial J Nutr. 2022
  26. The Efficacy of Palmitoylethanolamide (Levagen+) on the Incidence and Symptoms of Upper Respiratory Tract Infection - A Double Blind, Randomised, Placebo-Controlled Trial Nutrients. 2023